U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C14H17ClN2O
Molecular Weight 264.751
Optical Activity UNSPECIFIED
Defined Stereocenters 1 / 1
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of PNU-282987 FREE BASE

SMILES

ClC1=CC=C(C=C1)C(=O)N[C@H]2CN3CCC2CC3

InChI

InChIKey=WECKJONDRAUFDD-ZDUSSCGKSA-N
InChI=1S/C14H17ClN2O/c15-12-3-1-11(2-4-12)14(18)16-13-9-17-7-5-10(13)6-8-17/h1-4,10,13H,5-9H2,(H,16,18)/t13-/m0/s1

HIDE SMILES / InChI

Molecular Formula C14H17ClN2O
Molecular Weight 264.751
Charge 0
Count
Stereochemistry ABSOLUTE
Additional Stereochemistry No
Defined Stereocenters 1 / 1
E/Z Centers 0
Optical Activity UNSPECIFIED

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/27729414

PNU-282987 is a potent and selective a7 nAChR agonist. This compound showed high affinity for the rat a7 nAChR (Ki = 26 nM) and activity at the a7–5-HT3 chimera (EC50 = 128 nM). In addition, PNU-282987 was found to be inactive at all tested monoamine, muscarine, glutamate, and GABA receptors at 1 uM concentration, except 5-HT3 receptors (Ki = 930 nM). The highly selective and potent a7 nAChR agonist PNU-282987 enhances GABAergic synaptic activity in the hippocampus in vitro, and reverses amphetamine induced auditory gating deficit in anesthetized rats. In addition, PNU-282987 improves the inherent gating deficit observed in a subset of rats and enhances amphetamine induced hippocampal activity. These results support the concept that a7 nAChR agonists represent a novel, potential pharmacotherapy in treatment of schizophrenia. It also has being shown that acute lung injury is reduced by PNU-282987 through changes in the macrophage profile.

Originator

Curator's Comment: # Pfizer

Approval Year

TargetsConditions

Conditions

PubMed

PubMed

TitleDatePubMed
Interaction of bispyridinium compounds with the orthosteric binding site of human α7 and Torpedo californica nicotinic acetylcholine receptors (nAChRs).
2011-09-25
Neurotoxicity induced by okadaic acid in the human neuroblastoma SH-SY5Y line can be differentially prevented by α7 and β2* nicotinic stimulation.
2011-09
Human platelets express functional alpha7-nicotinic acetylcholine receptors.
2011-04
Alpha7 nicotinic acetylcholine receptor activation ameliorates scopolamine-induced behavioural changes in a modified continuous Y-maze task in mice.
2009-01-05
The selective alpha7 nicotinic acetylcholine receptor agonist PNU-282987 [N-[(3R)-1-Azabicyclo[2.2.2]oct-3-yl]-4-chlorobenzamide hydrochloride] enhances GABAergic synaptic activity in brain slices and restores auditory gating deficits in anesthetized rats.
2005-03
Patents

Sample Use Guides

In Vivo Use Guide
Curator's Comment: Can also be used i.p. (0.3mg/kg and 1.0mg/kg) https://www.ncbi.nlm.nih.gov/pubmed/24833065 or s.c. (10mg/kg) https://www.ncbi.nlm.nih.gov/pubmed/20630711
Rats: eye drops of PNU-282987 resulted in neuroprotection against etinal ganglion cells (RGCs) loss in a dose-dependent manner using concentrations between 100 uM and 2 mM PNU-282987
Route of Administration: Topical
PNU-282987 (1, 3, and 10 uM) incubated for 16 h after the 8-h rot/oligo period in SH-SY5Y cells produced a concentration-dependent protective effect; the maximum protective effect was achieved with 10 uM PNU282987 (50% neuroprotection)
Substance Class Chemical
Created
by admin
on Mon Mar 31 22:53:36 GMT 2025
Edited
by admin
on Mon Mar 31 22:53:36 GMT 2025
Record UNII
27M563MU5U
Record Status Validated (UNII)
Record Version
  • Download
Name Type Language
BENZAMIDE, N-(3R)-1-AZABICYCLO(2.2.2)OCT-3-YL-4-CHLORO-
Preferred Name English
PNU-282987 FREE BASE
Common Name English
Code System Code Type Description
FDA UNII
27M563MU5U
Created by admin on Mon Mar 31 22:53:36 GMT 2025 , Edited by admin on Mon Mar 31 22:53:36 GMT 2025
PRIMARY
PUBCHEM
9795278
Created by admin on Mon Mar 31 22:53:36 GMT 2025 , Edited by admin on Mon Mar 31 22:53:36 GMT 2025
PRIMARY
EPA CompTox
DTXSID701018122
Created by admin on Mon Mar 31 22:53:36 GMT 2025 , Edited by admin on Mon Mar 31 22:53:36 GMT 2025
PRIMARY
CAS
711085-63-1
Created by admin on Mon Mar 31 22:53:36 GMT 2025 , Edited by admin on Mon Mar 31 22:53:36 GMT 2025
PRIMARY
Related Record Type Details
TARGET -> AGONIST
PNU-282,987: A SELECTIVE AND POTENT AGONIST, BUT MAY CAUSE LONG QT SYNDROME.
Related Record Type Details
ACTIVE MOIETY